The Athletics Integrity Unit (AIU) has handed Ethiopia’s Gudaf Tsegay a four-month suspension following an Anti-Doping Rule Violation (ADRV). The decorated two-time World Champion and Olympic medallist admitted to the presence of a metabolite of Letrozole, concluding the matter via a Case Resolution Agreement.
The 29-year-old middle- and long-distance star was sanctioned under World Athletics Anti-Doping Rules (ADR) Rule 2.1 (Presence of a Prohibited Substance) and Rule 2.2 (Use or Attempted Use). Tsegay’s period of ineligibility commenced on June 1, 2026—the date she accepted the agreement—and will run through September 30, 2026.
The paper trail and the retroactive TUE
The positive test stems from an out-of-competition sample collected on December 5 of last year. Letrozole is classified as an aromatase inhibitor under section S4.1 of the WADA Prohibited List and is banned at all times.
When notified of the adverse analytical finding by the AIU on January 26, 2026, Tsegay responded immediately. The following day, she provided comprehensive medical documentation showing she had been prescribed the medication to treat a diagnosed medical condition.
On February 17, Tsegay applied for a Therapeutic Use Exemption (TUE). The World Athletics TUE Committee (WATUEC) later confirmed that her situation met all the necessary criteria under Article 4.2 of WADA’s International Standard:
- The substance was required to treat a legitimate medical condition.
- No reasonable permitted therapeutic alternative existed.
- The use would not produce additional performance enhancement beyond returning to a normal state of health.
However, the case hit a roadblock when an application for an exceptional retroactive TUE under Article 4.3 was rejected by WADA. Because the exemption was not secured before testing, the violation stood.
Mitigation and the shortened sanction
Ultimately, the AIU and WADA agreed that a reduced four-month ban was appropriate under Rule 10.6.1(a) (No Significant Fault or Negligence).
The governing bodies based the abbreviated sanction on several mitigating factors:
- Tsegay’s degree of fault was deemed low.
- She offered a prompt admission of the violation.
- She successfully demonstrated that she would have been granted a TUE had she applied for it before the out-of-competition test.
AIU Editor’s Note: While the ruling confirms no intentional performance-enhancing intent, the case serves as a stark reminder of the strict liability principle in modern athletics. Failing to secure administrative paperwork before a substance enters the system remains a costly misstep, even for the sport’s biggest stars.
An online search found the following information from USADA.org:
Athletes use Letrozole—a potent aromatase inhibitor (AI) primarily used to treat breast cancer—to manipulate their hormones. It is strictly prohibited by the World Anti-Doping Agency (WADA) at all times. Athletes typically use it for three main reasons:
Managing steroid side effects: When athletes abuse anabolic-androgenic steroids, the body often converts those excess androgens into estrogen. Letrozole blocks this process, preventing unwanted feminizing side effects like breast development (gynecomastia) and severe water retention.
Boosting testosterone: By suppressing estrogen, Letrozole signals the pituitary gland to increase the body’s natural testosterone production. This aids in building muscle mass and improving overall athletic output.
Masking steroid use: It is sometimes used to hide the traces of anabolic steroid abuse in drug tests.
Tsegay is one of the fastest and most consistent middle and long-distance runners of all time. Her personal bests include a 3:50.30 in the 1500 metre event run in 2024. Her 10,000m best is 29:05.92, also from 2024 and her 5000m best is 14:00.21 from 2023. She holds two national records in the 5000m and mile (1609m) 4:11.88 from 2025.
